AB Pharma has independently developed the new anti-HCV drug ZN2007. ZN2007 has the big ring structure of the second generation protease inhibitors with better curative effect, and is added self-designed and innovative polycyclic heterocyclic functional groups. ZN2007 could directly affect the NS3/4A serine protease of HCV and inhibit the proliferation of HCV to achieve the goal of healing and rehabilitation. The new drug has been patented worldwide and licensed.

The result of pharmacodynamic research shows that the new anti-HCV drug (ZN2007) developed by AB Pharma is superior to other same targeted drugs in inhibiting NS3/4A protease, HCV replicons and Hepatitis C whole viruses.

021-5442 6122
©2018 AB Pharma Ltd. All rights reserved
沪公网安备 33311802006333号 沪CP备12345767号
Technical Support:www.51eway.com
No. 99, Lane 133, Guangzhong Road, Shanghai